Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 013

Next Previous
Drug Profile

B 013

Alternative Names: B-013

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Triple negative breast cancer
  • Phase II Breast cancer; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Ovarian cancer

Most Recent Events

  • 11 Jul 2024 Phase-II clinical trials in Ovarian cancer (Combination therapy, Recurrent; Treatment-resistant) in China (IV) (NCT06434610)
  • 30 May 2024 Shanghai Pharmaceutical Group plans a phase II trial for Ovarian cancer (Second-line therapy or greater, Recurrent, In adults, In the elderly) (IV), in June 2024 (NCT06434610)
  • 06 Dec 2022 Phase-II/III clinical trials in Triple-negative-breast-cancer (First-line therapy, Combination therapy, Metastatic disease, Late-stage disease) in China (IV) (NCT05555706)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top